Navidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.24 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.